StockData
BioNexus Gene Lab Corp logo

BioNexus Gene Lab Corp (BGLC) stock

BGLCNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 8/3090% below fair value
$0.77−0.05 (-6.56%)

Close on Nov 17, 2026Market cap $2.25MP/E –Yield –

BioNexus Gene Lab pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

BioNexus Gene Lab's pe ratio was 670.6× on Aug 31, 2020.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2020Aug 31, 2020670.6×–

More BioNexus Gene Lab figures

See a number that looks wrong?